Back to Search
Start Over
Atorvastatin, but not pravastatin, inhibits cardiac Akt/mTOR signaling and disturbs mitochondrial ultrastructure in cardiac myocytes
- Source :
- The FASEB Journal. 33:1209-1225
- Publication Year :
- 2018
- Publisher :
- Wiley, 2018.
-
Abstract
- Statins, which reduce LDL-cholesterol by inhibition of 3-hydroxy-3-methylglutaryl–coenzyme A reductase, are among the most widely prescribed drugs. Skeletal myopathy is a known statin-induced adverse effect associated with mitochondrial changes. We hypothesized that similar effects would occur in cardiac myocytes in a lipophilicity-dependent manner between 2 common statins: atorvastatin (lipophilic) and pravastatin (hydrophilic). Neonatal cardiac ventricular myocytes were treated with atorvastatin and pravastatin for 48 h. Both statins induced endoplasmic reticular (ER) stress, but only atorvastatin inhibited ERK1/2(T202/Y204), Akt(Ser473), and mammalian target of rapamycin signaling; reduced protein abundance of caveolin-1, dystrophin, epidermal growth factor receptor, and insulin receptor-β; decreased Ras homolog gene family member A activation; and induced apoptosis. In cardiomyocyte-equivalent HL-1 cells, atorvastatin, but not pravastatin, reduced mitochondrial oxygen consumption. When male mice underwent atorvastatin and pravastatin administration per os for up to 7 mo, only long-term atorvastatin, but not pravastatin, induced elevated serum creatine kinase; swollen, misaligned, size-variable, and disconnected cardiac mitochondria; alteration of ER structure; repression of mitochondria- and endoplasmic reticulum–related genes; and a 21% increase in mortality in cardiac-specific vinculin-knockout mice during the first 2 months of administration. To our knowledge, we are the first to demonstrate in vivo that long-term atorvastatin administration alters cardiac ultrastructure, a finding with important clinical implications.—Godoy, J. C., Niesman, I. R., Busija, A. R., Kassan, A., Schilling, J. M., Schwarz, A., Alvarez, E. A., Dalton, N. D., Drummond, J. C., Roth, D. M., Kararigas, G., Patel, H. H., Zemljic-Harpf, A. E. Atorvastatin, but not pravastatin, inhibits cardiac Akt/mTOR signaling and disturbs mitochondrial ultrastructure in cardiac myocytes.
- Subjects :
- Male
0301 basic medicine
Cell Survival
medicine.medical_treatment
Atorvastatin
Pharmacology
Mitochondrion
Biochemistry
Mitochondria, Heart
Cell Line
Mice
03 medical and health sciences
0302 clinical medicine
Genetics
Animals
Myocyte
Medicine
Myocytes, Cardiac
cardiovascular diseases
Creatine Kinase
Molecular Biology
Protein kinase B
Pravastatin
business.industry
TOR Serine-Threonine Kinases
Research
Insulin
Endoplasmic reticulum
nutritional and metabolic diseases
Cholesterol, LDL
Vinculin
030104 developmental biology
Apoptosis
lipids (amino acids, peptides, and proteins)
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Transcriptome
rhoA GTP-Binding Protein
business
Proto-Oncogene Proteins c-akt
030217 neurology & neurosurgery
Signal Transduction
Biotechnology
medicine.drug
Subjects
Details
- ISSN :
- 15306860 and 08926638
- Volume :
- 33
- Database :
- OpenAIRE
- Journal :
- The FASEB Journal
- Accession number :
- edsair.doi.dedup.....c0e4fdad358c04272bf15370c3e9cfdd